retatrutide and semaglutide vs. Ozempic: The Triple Agonist That May Change Everything., hits one receptor. Retatrutide hits three., That difference may be the biggest leap in metabolic medicine since , Retatrutide vs. Tirzepatide vs. Semaglutide

Furthermore, its short half-life of less than 3 h (Min et al., 2025) necessitates twice-daily injections to maintain efficacy, which can be a limiting factor for long-term patient adherence

Scientific Review Educational information presented on this page has been reviewed by the Regentide Research Team for scientific accuracy, literature review standards, and Research Use Only compliance

Effects of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a systematic review and meta-analysis

Seeking Alpha's Disclosure: Past performance is no guarantee of future results

Our approach focuses on the whole patient